Gst Apl-01 Form Download
Chieko Aldana
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
To confirm that these phenotypes were caused by loss of apl-1, we transformed apl-1 heterozygotes with an 8.45-kb apl-1 genomic fragment and recovered transgenic homozgyous apl-1 progeny that were rescued for all apl-1 mutant phenotypes (SI Fig. 5). By contrast, the same genomic fragment containing point mutations in the coding region failed to rescue the apl-1 lethality (SI Fig. 5). Expression of an APL-1::GFP fusion protein using apl-1 regulatory sequences also rescued the lethality (Fig. 1B). Together, these data indicate that the observed phenotypes result specifically from loss of apl-1 function. The early lethality in apl-1 mutants hampers an examination of apl-1 function after the first molt, so the full extent of APL-1 activity is unknown.
To evaluate apl-1 transcript and protein levels in the mutants, we performed RT-PCR and Western blot analysis on yn10, yn23, and yn32 animals, which are homozygous for deletion, nonsense, and missense mutations, respectively; the mutant animals all carried rescue transgenes, which produce WT products that could be differentiated from the endogenous mutant apl-1 transcripts and proteins. apl-1 transcripts are detected in WT eggs, larvae, and adults (19). Similarly, mutant transcripts were isolated from all three mutants (data not shown). However, no endogenous mutant APL-1 protein was detected in any of the three strains (Fig. 1C), indicating that these three mutations are likely null alleles. The yn32 mutation causes a glutamic acid to lysine substitution at residue 372 in the E2 domain. In human APP the corresponding residue is not predicted to be important for the structural stability of E2 (20); however, this residue is proposed to be part of an α-helix that is necessary for APP cleavage (21). Animals carrying an apl-1(yn32)::GFP transgene express GFP faintly (data not shown), suggesting that yn32 animals die from insufficient levels of APL-1::yn32 protein because it is unstable, degraded quickly, or not cleaved to produce sAPL-1.
Transgenic animals overexpressing APL-1 also had subtle movement defects, which we quantified in two motor assays. When placed into physiological buffer, WT animals begin to swim, and the number of body flexures or thrashes per minute can be quantified (Table 1). All apl-1 transgenic overexpression strains showed a significantly reduced thrashing rate (Table 1). Second, on a solid surface WT animals move in a sinusoidal waveform, which can be quantified by counting the number of head bends per min. All transgenic overexpression strains had a decreased head bend rate compared with WT (Table 1). Furthermore, a transgenic line that was homozygous for two integrated transgenes produced higher levels of APL-1 (Fig. 1D and SI Table 2) and was more sluggish than either parental line alone (Table 1). Increasing levels of APL-1, therefore, inhibit movement, perhaps by interfering with motor neuron functions.
Each micro-credential for Level II teachers is self-paced with online quizzes to check for understanding. At the end of a micro-credential is a Mastery Component. The Mastery Component is a performance task designed to provide an opportunity for the teacher to demonstrate understanding of key concepts presented in the micro-credential. Mastery Component Reviewers are available to grade the Mastery Component and provide meaningful feedback to the teacher to enhance learning. Teachers will have an opportunity to resubmit the Mastery Component not meeting the expected score of 85% within a 10-day resubmission window. Reviewers will provide guidance as needed to assist in a successful resubmission of the Mastery Component.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) that is cytogenetically characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion of the promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARα) genes. Because patients with APL present a tendency for severe bleeding, often resulting in an early fatal course, APL was historically considered to be one of the most fatal forms of acute leukemia. However, therapeutic advances, including anthracycline- and cytarabine-based chemotherapy, have significantly improved the outcomes of APL patients. Due to the further introduction of all-trans retinoic acid (ATRA) and-more recently-the development of arsenic trioxide (ATO)-containing regimens, APL is currently the most curable form of AML in adults. Treatment with these new agents has introduced the concept of cure through targeted therapy. With the advent of revolutionary ATRA-ATO combination therapies, chemotherapy can now be safely omitted from the treatment of low-risk APL patients. In this article, we review the six-decade history of APL, from its initial characterization to the era of chemotherapy-free ATRA-ATO, a model of cancer-targeted therapy.
Sample Certification Forms Sorted By Specification Number
This web page contains a listing of those materials that are entered into the Laboratory Information Management System. By selecting a Material ID Number, you will be able to view an example of a certification form.
Materials Bulletins
The information provided in a Materials Bulletin is meant to function as an addendum to the contract documents. For questions for concerns regarding the information contained within these documents, please contact the related State Materials Office technical unit.
Sampling, Testing and Reporting Guide (STRG)
The STRG provides information on the frequency of the sampling and testing of materials. Both the STRG and the Job Guide Schedule (JGS) are now part of the MAC application. Instructions for both the STRG and the JGS can both be found on the MAC page and then going to the training section.
If you do not have your tax refund check and need a replacement, you should have received Form DTF-32, Notice to Owner of an Uncashed Check, automatically. Just complete, sign, and return it no later than the response date on the form.
With this setup, now we need a function to insert our separators where they belong. We want our separator to be placed at every 6th position, starting from the right, so I reversed an iota and performed a modulo.
The FAA announced CLEEN Phase III awardees on September 10, 2021. For more information on the CLEEN Program, its benefits, and accomplishments to date, see the CLEEN Program Summary and Status Report.
In addition to the aircraft technology development work under CLEEN, phases I and II of the program have supported fuel properties and performance testing and demonstrations. This testing facilitates new sustainable aviation fuel (SAF) approvals by standard setting organization ASTM International. For more information on the full scope of FAA's SAF activities, please see the Sustainable Aviation Fuels site.
The third phase of the CLEEN Program is focused on gathering test data to support the certification and qualification of greater than 50% blends of SAF with traditional petroleum-based jet fuels. This includes testing fuels with varying chemical compositions to determine compositional effects on seal performance, a current barrier to higher SAF blend volumes. Testing also includes combustor performance evaluations of synthetic aviation turbine fuels currently in the ASTM D4054 evaluation process, including fuels with unique chemical compositions such as a highly cycloparaffinic fuels.
The CLEEN program holds biannual consortium meetings occurring in May and November of each year. During the meeting companies provide detailed descriptions of the progress of their technology development projects. While the majority of the meeting consists of government-only review sessions, the meeting also includes one open day where companies share highlights of their work with the general public. Please contact cl...@faa.gov for more information.
df19127ead